Risk of diarrhoea due to Clostridium difficile during cefotaxime treatment. Cefotaxime compares favourably with other third generation cephalosporins

letter

. 1996 Mar 23;312(7033):778. doi: 10.1136/bmj.312.7033.778

Risk of diarrhoea due to Clostridium difficile during cefotaxime treatment. Cefotaxime compares favourably with other third generation cephalosporins.

PMCID: PMC2350484 PMID: 8605486

These references are in PubMed. This may not be the complete list of references from this article.

Bartlett J. G., Mundy L. M. Community-acquired pneumonia. N Engl J Med. 1995 Dec 14;333(24):1618–1624. doi: 10.1056/NEJM199512143332408. [DOI] [PubMed] [Google Scholar]
Impallomeni M., Galletly N. P., Wort S. J., Starr J. M., Rogers T. R. Increased risk of diarrhoea caused by Clostridium difficile in elderly patients receiving cefotaxime. BMJ. 1995 Nov 18;311(7016):1345–1346. doi: 10.1136/bmj.311.7016.1345. [DOI] [PMC free article] [PubMed] [Google Scholar]
Jones R. N. Gram-positive superinfections following beta-lactam chemotherapy: the significance of the enterococcus. Infection. 1985;13 (Suppl 1):S81–S88. doi: 10.1007/BF01644225. [DOI] [PubMed] [Google Scholar]
Meyers B. R. Comparative toxicities of third-generation cephalosporins. Am J Med. 1985 Aug 9;79(2A):96–103. doi: 10.1016/0002-9343(85)90268-2. [DOI] [PubMed] [Google Scholar]
Tabaqchali S., Jumaa P. Diagnosis and management of Clostridium difficile infection. BMJ. 1995 May 27;310(6991):1375–1380. doi: 10.1136/bmj.310.6991.1375. [DOI] [PMC free article] [PubMed] [Google Scholar]